Navigation Links
Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management
Date:10/19/2011

NEW YORK, Oct. 19, 2011 /PRNewswire/ -- Progenitor Cell Therapy ("PCT"), a wholly-owned subsidiary of NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), today announced key additions to its management team to meet the demands associated with its contract development and manufacturing activities, including those associated with NeoStem's other subsidiaries, which add to the PCT client list.  NeoStem is an international biopharmaceutical company with a focus on cell-based therapeutic development, and, through its acquisition of PCT, is solidifying its position as a leader in the development and manufacturing of cell therapies. The Company's strategic combination of revenues with manufacturing through its subsidiary, PCT, and global reach has positioned the Company for important advances in the cell therapy industry.  The success of PCT's client business has allowed the Company to expand its management and technical staff in order to grow revenue and advance these cell therapies towards commercialization.  

Timothy Fong, PhD, MBA, formerly of BD Biosciences, is joining PCT as Vice President, Technology and Product Development. David O'Neill, MD, formerly of New York University Medical Center, was recently appointed Director of Research and Development for the Company.

Dr. Fong brings with him significant experience from his previous position as Technical Director of the Cell Therapy Research Team, BD Biosciences, where, as part of the cell therapy enablement team, he was responsible for the development and manufacturing of conjugated antibody reagents for use in cell sorting for clinical cell therapeutic products. Prior to that role, Dr. Fong led a team at BD Biosciences in the development of a T Regulatory cell product for the treatment of GvHD and autoimmune diseases. This technology has since been licensed by NeoStem's Athelos subsidiary. While at NYU Medical Center, Dr. O'Neill led the design, construction, and validation of a new cGMP aseptic manufacturing facility at the NYU Cancer Institute and led the pre-clinical development, cGMP manufacturing, quality assurance and immune monitoring work for a novel autologous dendritic cell immunotherapy for malignant melanoma.

"Our acquisition of PCT is proving to be not only accretive but also generating  a cost savings for NeoStem while accelerating our mission to be a global leader in cell therapy," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "We are thrilled that such high caliber industry veterans have chosen to join PCT to assist us with our client-focused development and manufacturing and our growing portfolio of cellular therapeutic candidates." "Dr. Fong and Dr. O'Neill lend their considerable expertise to PCT's clients and to NeoStem's preclinical and clinical development programs," said Dr Robert Preti, President and Chief Scientific Officer of PCT.  "These key additions will add to our reputation in the industry as the "go-to" company to enable effective development and manufacturing of cellular therapeutics for our expanding client base."

About NeoStem, Inc.NeoStem is a leader in the development and manufacturing of cell therapies. The Company's strategic combination of revenues with manufacturing through its subsidiary, Progenitor Cell Therapy, LLC and global reach has positioned the company for breakthroughs in the cell therapy industry. The acquisition of Amorcyte, Inc., closed on October 17, 2011, positions NeoStem to achieve its mission of capturing the paradigm shift to cell therapy. NeoStem is also pursuing a T-cell therapeutic with potential in a range of auto-immune conditions and development of its VSEL™ Technology platform. For more information on NeoStem, please visit www.neostem.com.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's successful development of cell therapeutics, as well as the future of the cell therapeutics industry. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's prospectus supplement filed with the Securities and Exchange Commission on September 30, 2011. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

For more information, please contact:Trout GroupNeoStem, Inc.Gitanjali Jain Ogawa, Vice PresidentRobin Smith, CEOPhone: +1-646-378-2949 Phone: +1-212-584-4174Email: gogawa@troutgroup.comEmail: rsmith@neostem.com
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Progenitor Cell Therapy Secures Industry Accreditation
2. NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC
3. Progenitor Cell Therapy Appoints VP of Manufacturing Operations
4. Progenitor Cell Therapy Expands Manufacturing Operations
5. NeoStem Presented at NASDAQ MarketSite in New York to Discuss Entry Into Merger Agreement With Progenitor Cell Therapy
6. NeoStem Acquires Progenitor Cell Therapy
7. Progenitor Cell Therapy to Present at 6th Annual New York Stem Cell Summit on Tuesday, March 1
8. Texas Teen Opts for Stem Cell Therapy, Hopes of Enlisting in Military
9. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
10. JAG Media Holdings, Inc. Announces Letter of Intent for the Acquisition of CardioGenics Inc. by a Wholly-Owned Subsidiary of JAG Media
11. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... NEW YORK , May 26, 2016 ... industry, investors see value in this space. Today,s pre-market research ... Healthcare equities: Radius Health Inc. (NASDAQ: RDUS ), ... (NASDAQ: ARWR ), and Five Prime Therapeutics Inc. ... these stock technical briefings at: http://www.activewallst.com/ ...
(Date:5/26/2016)... ... May 26, 2016 , ... Kinder Scientific (KinderScientific.com), a ... that position the Company for the future. Kinder Scientific announces restructured ownership ... has been appointed Chairman of the Board, Curtis D. Kinghorn has been appointed ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lajollacooks4u has become a rising hotspot for ... one of its top attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, Qualcomm ... and intimate team-building experience. , Each event kicks off with an olive oil and ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Ankle ... plating options designed to address fractures of the distal tibia and fibula. This ... Acumed Ankle Plating System 3 is composed of seven plate families that span ...
Breaking Biology Technology:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
Breaking Biology News(10 mins):